Marker Therapeutics MRKR
NASDAQ MRKR
$1.05 -0.02 (-1.87%)
At close: Oct 1, 2026 · 4:00 PM EDT

Marker Therapeutics (MRKR) Non-Current Debt (2015)

Updated

Marker Therapeutics (MRKR) posted Non-Current Debt of $85,222 for Q4 2012, up 328.3% from $19,900 a year earlier and up 40.2% from the prior quarter.

Analysis

Marker Therapeutics (MRKR) Non-Current Debt (2015) Analysis & Trends

For FY2012, Marker Therapeutics' Non-Current Debt came in at $205,543.

  • In prior years, Marker Therapeutics' Non-Current Debt was -$11,400 in FY2011 and $243,205 in FY2010.
  • The Q4 2012 figure stands as the highest quarterly Non-Current Debt since Q4 2010.
  • On a year-over-year basis, Non-Current Debt increased in three of the last four quarters, with growth averaging 156.0%.
  • According to Business Quant data, Non-Current Debt for the three prior quarters was $60,777 (Q3 2012), $38,644 (Q2 2012) and $20,900 (Q1 2012).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 37.34 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 62.48 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 51.08 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -108.00 Mn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 51.86 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 23.83 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 60.50 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Marker Therapeutics 17.87 Mn -42.04 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2015 23,000.00
Jun 30, 2015 23,000.00
API Access

Marker Therapeutics Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=MRKR&period=max&api_key=YOUR_API_KEY